WAVE Life Sciences Ltd.
WVE
$5.73
-$0.34-5.60%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -30.42% | -31.58% | -60.55% | 103.75% | -14.98% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -30.42% | -31.58% | -60.55% | 103.75% | -14.98% |
| Cost of Revenue | 16.18% | 13.63% | 14.46% | 17.10% | 21.77% |
| Gross Profit | -73.78% | -90.25% | -172.58% | 31.54% | -161.52% |
| SG&A Expenses | 27.17% | 23.89% | 27.63% | 24.79% | 23.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.30% | 16.47% | 18.02% | 19.21% | 22.28% |
| Operating Income | -51.85% | -56.56% | -95.09% | 10.59% | -71.47% |
| Income Before Tax | -55.90% | -63.44% | -110.68% | 14.43% | -75.12% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -55.90% | -63.44% | -110.68% | 14.43% | -76.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -55.90% | -63.44% | -110.68% | 14.43% | -76.74% |
| EBIT | -51.85% | -56.56% | -95.09% | 10.59% | -71.47% |
| EBITDA | -53.32% | -58.56% | -98.99% | 10.50% | -76.27% |
| EPS Basic | -23.31% | -27.41% | -54.80% | 33.84% | -51.76% |
| Normalized Basic EPS | -23.33% | -27.44% | -54.78% | 33.85% | -50.71% |
| EPS Diluted | -21.75% | -25.69% | -52.60% | 33.09% | -52.52% |
| Normalized Diluted EPS | -21.76% | -25.71% | -52.57% | 32.83% | -52.49% |
| Average Basic Shares Outstanding | 21.18% | 21.48% | 22.00% | 30.90% | 30.81% |
| Average Diluted Shares Outstanding | 19.11% | 19.28% | 19.66% | 33.05% | 32.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |